Business
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.
About this update from Hua Medicine Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"First glucokinase-activator (GKA) approval outside mainland China ","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Approval supports a differentiated approach to Type 2 diabetes (T2D) management","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Hong Kong will serve as Hua Medicine's launchpad for international market expansion","length":92,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":246,"olType":false},{"type":"text","content":"SHANGHAI and HONG KONG, March 3, 2026 /PRNewswire/ -- Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.","length":450,"tagName":"p"},{"type":"text","content":"Under Hong Kong's "1+" pharmaceutical regulatory innovation mechanism, the approval follows the acceptance of dorzagliatin's New Drug Application (NDA) by the Hong Kong Department of Health in September 2025. As the first innovative drug for chronic metabolic diseases approved for marketing since the launch of "1+" mechanism, the successful rollout of dorzagliatin not only brings an entirely new treatment option for patients with Type 2 diabetes in Hong Kong, but also marks a crucial step in Hua Medicine's strategic layout to expand from China to the Southeast Asian and global markets with Hong Kong as its hub.","length":650,"tagName":"p"},{"type":"text","content":"Cao Beili, Vice President of Department of Corporate Operation and Great Bay Development of Hua Medicine, stated: "Among the three new drugs approved under the '1+' mechanism, MYHOMSIS® is an innovative medicine developed in China that has obtained approval from the National Medical Products Administration (NMPA). It is also the first primary care drug product approved under the '1+' mechanism."","length":424,"tagName":"p"},{"type":"text","content":"Dr. Chen Li, Founder, Executive Director and CEO of Hua Medicine, stated: "The approval of dorzagliatin for marketing in Hong Kong is a signif...